JP2009519238A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519238A5
JP2009519238A5 JP2008543436A JP2008543436A JP2009519238A5 JP 2009519238 A5 JP2009519238 A5 JP 2009519238A5 JP 2008543436 A JP2008543436 A JP 2008543436A JP 2008543436 A JP2008543436 A JP 2008543436A JP 2009519238 A5 JP2009519238 A5 JP 2009519238A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
bacterium
bacillus
seq
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008543436A
Other languages
English (en)
Japanese (ja)
Other versions
JP5280854B2 (ja
JP2009519238A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/045755 external-priority patent/WO2007064741A2/en
Publication of JP2009519238A publication Critical patent/JP2009519238A/ja
Publication of JP2009519238A5 publication Critical patent/JP2009519238A5/ja
Application granted granted Critical
Publication of JP5280854B2 publication Critical patent/JP5280854B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008543436A 2005-11-29 2006-11-29 消化器、および免疫‐関連疾患の予防または処置のためのバチルスｐｂ６の使用 Expired - Fee Related JP5280854B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74051805P 2005-11-29 2005-11-29
US60/740,518 2005-11-29
PCT/US2006/045755 WO2007064741A2 (en) 2005-11-29 2006-11-29 The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013069311A Division JP2013173750A (ja) 2005-11-29 2013-03-28 消化器、および免疫‐関連疾患の予防または処置のためのバチルスｐｂ６の使用

Publications (3)

Publication Number Publication Date
JP2009519238A JP2009519238A (ja) 2009-05-14
JP2009519238A5 true JP2009519238A5 (https=) 2010-01-28
JP5280854B2 JP5280854B2 (ja) 2013-09-04

Family

ID=38092773

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008543436A Expired - Fee Related JP5280854B2 (ja) 2005-11-29 2006-11-29 消化器、および免疫‐関連疾患の予防または処置のためのバチルスｐｂ６の使用
JP2013069311A Pending JP2013173750A (ja) 2005-11-29 2013-03-28 消化器、および免疫‐関連疾患の予防または処置のためのバチルスｐｂ６の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013069311A Pending JP2013173750A (ja) 2005-11-29 2013-03-28 消化器、および免疫‐関連疾患の予防または処置のためのバチルスｐｂ６の使用

Country Status (13)

Country Link
US (1) US20080057047A1 (https=)
EP (1) EP1956914B1 (https=)
JP (2) JP5280854B2 (https=)
KR (1) KR101470352B1 (https=)
CN (1) CN101448398B (https=)
AU (1) AU2006320613B2 (https=)
BR (1) BRPI0619364A2 (https=)
CA (1) CA2631289C (https=)
IL (1) IL191795A (https=)
NZ (1) NZ569244A (https=)
RU (1) RU2412241C2 (https=)
WO (1) WO2007064741A2 (https=)
ZA (1) ZA200804646B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56037B1 (sr) 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2009293213C1 (en) * 2008-09-17 2015-04-30 Bayer Cropscience Lp Method for using a Bacillus subtilis strain to enhance animal health
CN102369105A (zh) * 2008-09-24 2012-03-07 莱斯勒斯公司 在材料中引入耐热和/或耐压生物
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
WO2011111783A1 (ja) * 2010-03-12 2011-09-15 カルピス株式会社 大腸におけるビフィズス菌の増加及び減少抑制剤
EP2547348B1 (en) 2010-03-17 2015-05-20 Bayer Cropscience LP Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions
WO2012009712A2 (en) 2010-07-16 2012-01-19 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
US9107938B2 (en) 2010-09-30 2015-08-18 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
WO2012092469A2 (en) * 2010-12-29 2012-07-05 Cangene Corporation Clostridium difficile antigens
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
WO2014022572A1 (en) 2012-08-01 2014-02-06 Pacific Vet Group-Usa, Inc. Probiotic for amelioration of coccidiosis vaccine reaction
RU2534356C2 (ru) * 2012-10-04 2014-11-27 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Россельхозакадемии (ГНУ ИЭВСиДВ Россельхозакадемии) Способ контроля качества дезинфекции птицеводческих помещений
FR2999191B1 (fr) * 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
FR3007655B1 (fr) * 2013-06-28 2016-12-23 Lesaffre & Cie Souche bacillus subtilis pour le traitement et/ou la prevention de maladies inflammatoires chroniques
EP2923710A1 (en) 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora
AU2015292271B2 (en) * 2014-07-25 2020-09-10 The University Of Queensland Bacillus amyloliquefaciens probiotic compositions, methods of production, and methods of use
CA3000621C (en) 2014-09-30 2024-02-27 Auburn University Use of pectin or pectin-related saccharides to enhance efficacy of plant growth-promoting rhizobacteria (pgpr) strains for promoting growth and health in plants and animals
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
JP6595761B2 (ja) * 2014-12-19 2019-10-23 東亜薬品工業株式会社 バチルスアミロリキファシエンス菌株及び該菌株を含む抗菌組成物
AU2016209132B2 (en) * 2015-01-23 2021-07-01 Novozymes A/S Bacillus strains improving health and performance of production animals
US11331351B2 (en) 2015-01-23 2022-05-17 Novozymes A/S Bacillus strains improving health and performance of production animals
EP3261653B1 (en) 2015-01-23 2019-10-09 Novozymes A/S Bacillus subtilis subspecies
WO2016194427A1 (ja) * 2015-05-30 2016-12-08 日環科学株式会社 プロバイオティクス、あるいはプレバイオティクス、並びにその製造方法、微生物製剤、健康食品並びに医薬品
WO2017062175A1 (en) 2015-10-06 2017-04-13 Albert Einstein College Of Medicine, Inc. Microbial hyperswarmers and uses thereof
CN108347974B (zh) * 2015-10-26 2023-01-10 希杰维康株式会社 解淀粉芽孢杆菌菌株、谷物发酵物、其制备方法及其应用
RU2641979C1 (ru) * 2016-10-24 2018-01-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) Способ морфологической оценки влияния различных лекарственных форм железа для энтерального применения на тонкий отдел кишечника у экспериментальных животных
JP7104078B2 (ja) * 2017-06-30 2022-07-20 エボニック オペレーションズ ゲーエムベーハー プロバイオティクス活性がある枯草菌株
US20190289878A1 (en) * 2018-03-23 2019-09-26 Purina Animal Nutrition Llc Methods of feeding animals feed products containing direct-fed microbials
EP3801578B1 (en) * 2018-06-07 2023-08-30 Artugen Therapeutics Ltd. B. amyloliquefaciens strain and therapeutic use
JP7634884B2 (ja) * 2019-05-14 2025-02-25 オルメンデス・ソシエテ・アノニム 活性プロバイオティクス組成物の増強または不活性プロバイオティクス組成物の活性化のためのバチルス・アミロリクエファシエンスおよび／またはバチルス・サブティリスの使用、このようにして得られた組成物、ならびに関連方法
WO2020257769A1 (en) * 2019-06-21 2020-12-24 The Board Of Trustees Of The University Of Arkansas Bacillus isolate compositions and methods of using and producing the same
GB201911925D0 (en) 2019-08-20 2019-10-02 Sporegen Ltd Formulations for prevention or reduction of c. difficile infections
WO2021116983A1 (en) * 2019-12-11 2021-06-17 Artugen Therapeutics, Ltd. Edible products comprising bacterial strains and methods of use
US20210283199A1 (en) * 2020-03-13 2021-09-16 Kemin Industries, Inc. Method for controlling clostridium infection in animals
GB202013874D0 (en) * 2020-09-03 2020-10-21 Sporegen Ltd Treatment and prevention of viral infections
MX2023006676A (es) 2020-12-09 2023-07-04 Purina Animal Nutrition Llc Composiciones alimenticias y metodos para inhibir dermatitis ulcerosa focal.
CN113151069B (zh) * 2021-04-01 2022-07-26 安杰利(重庆)生物科技有限公司 一种枯草芽孢杆菌及其在制备抗菌肽、饲料中的应用
KR102546973B1 (ko) * 2021-10-20 2023-06-26 주식회사 리빙진 바실러스 밸레젠시스 Kh2-2 균주를 포함하는 면역증강용 조성물
WO2023220279A1 (en) * 2022-05-12 2023-11-16 Can Technologies, Inc. Compositions and methods for the treatment and prevention of campylobacter infection
CN115725461B (zh) * 2022-11-03 2024-03-19 东北农业大学 一株具有抗幽门螺杆菌作用的解淀粉芽孢杆菌及其应用
FR3158224A1 (fr) * 2024-01-12 2025-07-18 Lesaffre Et Compagnie Effet bénéfique d’une bactérie probiotique Bacillus subtilis dans la lutte contre les infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968493A (en) * 1986-06-30 1990-11-06 American Cyanamid Company Method for controlling chronic respiratory disease, fowl cholera and necrotic enteritis in avian species
US5352586A (en) * 1987-05-01 1994-10-04 Biogaia Ab Method of determining the presence of an antibiotic produced by Lactobacillus reuteri
ZA926834B (en) * 1991-09-09 1993-03-15 American Cyanamid Co Antibiotic LL-E19020 Gamma.
TW455591B (en) * 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) * 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
JP2879321B2 (ja) * 1996-03-14 1999-04-05 久保田 豊秋 動物用経口組成物
DE69707413T3 (de) * 1997-01-09 2009-07-02 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
FI110668B (fi) * 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
RU2246537C2 (ru) * 2002-11-11 2005-02-20 Закрытое акционерное общество "КУЛ" Штамм бактерий bacillus subtilis, используемый для получения пробиотического препарата, предназначенного для профилактики и лечения желудочно-кишечных заболеваний сельскохозяйственных животных, птицы и рыбы
US7247299B2 (en) * 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
JP4189224B2 (ja) * 2003-01-14 2008-12-03 株式会社カンサイ バチルス属に属する微生物及びそれを用いる防除剤
KR100535912B1 (ko) * 2003-12-17 2005-12-09 주식회사 케이티앤지 신규한 미생물 바실러스 아밀로리쿼페이션스 케이티지비0202 및 이를 이용한 식물병원균의 방제방법
JP2005198518A (ja) * 2004-01-13 2005-07-28 Asahi Business Support Co Ltd 海苔屑分解処理法及び微生物
RU2270858C2 (ru) * 2004-03-30 2006-02-27 Институт биологии Уфимского научного центра РАН Штамм бактерий b. subtilis - продуцент сурфактина
US7854927B2 (en) * 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders

Similar Documents

Publication Publication Date Title
JP2009519238A5 (https=)
RU2008121602A (ru) Применение рв6 bacillus для профилактики или лечения желудочно- кишечных и иммунных заболеваний
JP6444358B2 (ja) ペディオコッカスを含有する医薬組成物および消化器症候群の症状を低減する方法
Zhou et al. Lactobacillus plantarum ZJ316 attenuates Helicobacter pylori-induced gastritis in C57BL/6 mice
Wullt et al. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial
HRP20191096T1 (hr) Sastavi koje sadrže bakterijske blautia sojeve za liječenje visceralne hipersenzitivnosti
HRP20190659T1 (hr) Kompozicije koje sadrže bakterijsku vrstu blautia hydrogenotrophica za upotrebu u liječenju ili prevenciji dijareje ili konstipacije
JP2021527104A5 (https=)
RU2011139211A (ru) Бактериальные штаммы, обладающие высокой противовоспалительной активностью
US20200121740A1 (en) Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
EP3681470A1 (en) New use for treatment of clostridium difficile infections
JP2019508486A5 (https=)
WO2002016554A9 (en) Probiotics products containing lactic acid bacterium
JP2014512376A (ja) 胃酸過多症の薬理学的処置中に失われる胃のバリア効果を回復させることができるプロバイオティック細菌を含む組成物
JP2016529309A5 (https=)
MX2009010252A (es) Combinacion simbiotica para mejorar la microbiota intestinal.
RU2010142003A (ru) Синбиотическая смесь
JP2013522315A5 (https=)
Fayed et al. Co-administration of amoxicillin-loaded chitosan nanoparticles and inulin: A novel strategy for mitigating antibiotic resistance and preserving microbiota balance in Helicobacter pylori treatment
NZ603065A (en) Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions
WO2010125421A1 (en) Use of collinsella aerofaciens for reducing bloating
JP2013147469A5 (https=)
JP2015525566A5 (https=)
Jin et al. Prebiotic effects of poly-gamma-glutamate on bacterial flora in murine gut
O'Sullivan Genomics can advance the potential for probiotic cultures to improve liver and overall health